about
Practical communication guidance to improve phase 1 informed consent conversations and decision-making in pediatric oncologyEthics consultation in pediatrics: long-term experience from a pediatric oncology center.Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancerIntegrating Palliative Care in Pediatric Oncology: Evidence for an Evolving Paradigm for Comprehensive Cancer CareEnd-of-life care for hospitalized children.Ethical considerations surrounding germline next-generation sequencing of children with cancer.The bereavement experience of adolescents and early young adults with cancer: Peer and parental loss due to death is associated with increased risk of adverse psychological outcomes.Management of Concurrent Pregnancy and Acute Lymphoblastic Malignancy in Teenaged Patients: Two Illustrative Cases and Review of the LiteraturePalliative Sedation With Propofol for an Adolescent With a DNR Order.Ethical decision making about end-of-life care issues by pediatric oncologists in economically diverse settings.International Child Health Competencies.Predictors of Late Palliative Care Referral in Children with Cancer.Navigating Nondisclosure Requests in Pediatrics: Honesty and Sensitivity Are Transcultural Practices.Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics.Clinically Significant? Depends on Whom You AskThe Need for Improved Access to Mental Health Services for Youth With Medically Unexplained SymptomsRecruiting Children for Clinical Trials: Lessons From Pediatric OncologyPredictors of Location of Death for Children with Cancer Enrolled on a Palliative Care ServiceAn unusual case of Ogilvie syndrome in a pediatric oncology patient receiving palliative care after failed treatment with neostigmineResponse to the Letter to the Editor from BleyerAn Extravagant Gift From a Grateful PatientThe role of the pediatric anesthesiologist in relieving suffering at the end of life: when is palliative sedation appropriate in pediatrics?A Pragmatic Trial of Suicide Risk Assessment and Ambulance Transport Decision Making Among Emergency Medical Services Providers: Implications for Patient ConsentA Cluster Randomized Trial to Screen for Abusive Head Trauma in the Pediatric Intensive Care Unit-How to Manage Site-Specific Evidence of Racial/Ethnic DisparityGreater Than Minimal Risk, No Direct Benefit - Bridging Drug Trials and Novel Therapy in Pediatric PopulationsEthical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease ResearchBringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal RiskAre we meeting the informational needs of cancer patients and families? Perception of physician communication in pediatric oncologyEthical issues in the care of adolescent and young adult oncology patientsShould Poor Social Support Be an Exclusion Criterion in Bone Marrow Transplantation?Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2-visit consent model
P50
Q35812000-B3D272F1-F994-4072-9952-60128B0A2DFBQ36388347-C7E112EF-D4CF-4876-A636-F80E92F13433Q36389862-694EF238-F20B-4B76-8A0D-3382298A0DDFQ37710270-BF9C3CF4-5DF6-46F8-8EC5-976E7D6F5562Q38236090-0595FB70-7D10-459A-8C83-A43FEBA66CBDQ39235246-C7B809B1-B615-4E32-82A7-BA3699B72955Q41498671-EBE33A76-12C2-4849-8433-9BF1F14D3C27Q42552235-50E219D6-243C-412E-BFC3-2D6242927700Q47277597-38CC659D-DD5C-42DB-BA35-BC7B75922DB0Q48040674-6060FCA0-68A8-4D83-B4B2-FBC7EC89BA4EQ49071565-277B83E5-69E8-49C2-AC94-F19F9B57CA0CQ50086385-73810A3C-763C-41F0-B22A-EF91D10B1614Q50222107-D150878F-98B1-468A-A8A4-4E0BC2DFB4D3Q55384079-E5702261-9E2D-4181-9E43-9B682E46311AQ57989046-06F5A47E-72FB-42B0-BE00-CF935101650FQ57989085-35886355-2D8D-4B6C-A0F3-961D203AD566Q57989502-75C57AB1-2790-4692-AC67-AA0CF045F54EQ62023543-04D4602F-2C9F-42E8-BF05-A4D3869E3318Q84931771-62A1254B-2508-4730-A7B4-E31FE5B8E6A5Q87161295-41F2E105-3C7E-4DBC-BA0D-FD8CCCFCBDEFQ88573632-66AD6150-3A55-4B58-B052-3A18877E3612Q89540275-34E01247-2602-482F-B1B1-2B00D7EEC641Q90305106-9EA2EF5D-3A64-452C-8268-1C50E598DFE8Q90305166-999369C0-4155-477C-920D-16173F7A5602Q90621300-CA106BCB-8062-4A24-AA7D-FA91DFF24006Q90621316-CFB72C17-19FD-44A5-9742-5CAE6CE33614Q90621343-6CD8D62D-5860-4E3B-AF13-2519108BBBCFQ90728388-9F89663D-37BB-47F8-AEB8-5EF850F36E66Q90850796-61A022AA-D8B7-47DE-887E-77648B3E850AQ90955724-EFE0647F-DB86-4C20-913C-C38CE8434134Q90985918-50577A8D-EC75-455C-BAC6-0EE169C89FEEQ92551872-AC692B97-928C-408F-9781-1EE5A9C7825B
P50
description
researcher ORCID ID = 0000-0002-7124-979X
@en
wetenschapper
@nl
name
Liza-Marie Johnson
@ast
Liza-Marie Johnson
@en
Liza-Marie Johnson
@es
Liza-Marie Johnson
@nl
type
label
Liza-Marie Johnson
@ast
Liza-Marie Johnson
@en
Liza-Marie Johnson
@es
Liza-Marie Johnson
@nl
prefLabel
Liza-Marie Johnson
@ast
Liza-Marie Johnson
@en
Liza-Marie Johnson
@es
Liza-Marie Johnson
@nl
P21
P31
P496
0000-0002-7124-979X